SANA BIOTECHNOLOGY INC (SANA) Stock Price & Overview
NASDAQ:SANA • US7995661045
Current stock price
The current stock price of SANA is 3.2 USD. Today SANA is up by 4.92%. In the past month the price decreased by -6.16%. In the past year, price increased by 116.22%.
SANA Key Statistics
- Market Cap
- 853.984M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.79
- Dividend Yield
- N/A
SANA Stock Performance
SANA Stock Chart
SANA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SANA. When comparing the yearly performance of all stocks, SANA is one of the better performing stocks in the market, outperforming 88.31% of all stocks.
SANA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SANA. The financial health of SANA is average, but there are quite some concerns on its profitability.
SANA Earnings
SANA Forecast & Estimates
15 analysts have analysed SANA and the average price target is 8.84 USD. This implies a price increase of 176.25% is expected in the next year compared to the current price of 3.2.
SANA Groups
Sector & Classification
SANA Financial Highlights
Over the last trailing twelve months SANA reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS increased by 31.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.57% | ||
| ROE | -151.77% | ||
| Debt/Equity | 0 |
SANA Ownership
SANA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SANA
Company Profile
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
Company Info
IPO: 2021-02-04
SANA BIOTECHNOLOGY INC
188 East Blaine Street, Suite 400
Seattle WASHINGTON 98102 US
CEO: Steven D. Harr
Employees: 142
Phone: 12067017914
SANA BIOTECHNOLOGY INC / SANA FAQ
Can you describe the business of SANA BIOTECHNOLOGY INC?
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 142 full-time employees. The company went IPO on 2021-02-04. The company is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. The company develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The firm is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
What is the current price of SANA stock?
The current stock price of SANA is 3.2 USD. The price increased by 4.92% in the last trading session.
Does SANA stock pay dividends?
SANA does not pay a dividend.
How is the ChartMill rating for SANA BIOTECHNOLOGY INC?
SANA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists SANA stock?
SANA stock is listed on the Nasdaq exchange.
When does SANA BIOTECHNOLOGY INC (SANA) report earnings?
SANA BIOTECHNOLOGY INC (SANA) will report earnings on 2026-05-06, after the market close.